Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-729 + nucleos(t)ide analogue
- Development stage
- Unknown
- Lead developer
- Arbutus Biopharma
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous (AB-729), Oral (nucleos(t)ide Analogue)
01
Overview
This drug is a **combination therapy** consisting of AB-729 (Imdusiran), a GalNAc-conjugated small interfering ribonucleic acid (siRNA) therapeutic, and a nucleos(t)ide analogue (NA), typically used for the treatment of **chronic hepatitis B (CHB)**. AB-729 targets HBV-infected hepatocytes via N-acetylgalactosamine (GalNAc) conjugation and inhibits hepatitis B virus protein and antigen production including hepatitis B surface antigen (HBsAg), which may break immune tolerance and restore anti-HBV T-cell activity. The nucleos(t)ide analogue (e.g., tenofovir or entecavir) inhibits HBV replication by blocking the reverse transcriptase activity of viral polymerase. Together, this combination aims for profound and sustained decreases in HBsAg in CHB patients, with the goal of enabling functional cure through viral suppression and immune reawakening[1][5][6][7]. Clinical data indicate this regimen is well tolerated and leads to meaningful HBsAg and HBV DNA reductions[1][3][5][7].
- Brand names
- Imdusiran
- Other names
- AB-729 + nucleos(t)ide analogueAB-729 plus NAAB729 plus NAAB 729 plus NAImdusiran + nucleos(t)ide analogue
02
Targets
HBV Pol (Hepatitis B virus polymerase)HBV X RNA (Hepatitis B virus X region RNA transcript)
Beyond the preview
Go deeper on AB-729 + nucleos(t)ide analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-729 + nucleos(t)ide analogue.